Our first US manufacturing facility for diabetes and obesity medicines was established in Clayton, NC in 1993. The facility has expanded rapidly to meet the increasing demand for our products, both locally and globally. We are now investing $2 billion in a new active pharmaceutical ingredient production facility in Clayton, and, we are opening a new tableting and packaging facility in Durham, NC to support an innovative new diabetes treatment.
In the Community
In the community, Novo Nordisk is committed to making a difference in North Carolina. We partner with policymakers to address the community’s needs for improved diabetes and obesity care and provide support for and partner with organizations that share similar visions and goals. Other organizations we work with on the front lines include: